Key result
Targeting NOX2 in a multi-center pre-clinical randomized confirmatory trial failed to improve neurofunctional outcomes or achieve a translationally relevant reduction in infarct size.
RCT
Randomized
Yes
Answers are grounded in this paper and cite their sources.
Biomedical research suffers from a dramatically poor translational success. For example, in ischemic stroke, a condition with a high medical need, over a thousand experimental drug targets were unsuccessful. Here, we adopt methods from clinical research for a late-stage pre-clinical meta-analysis (MA) and randomized confirmatory trial (pRCT) approach. A profound body of literature suggests NOX2 to be a major therapeutic target in stroke. Systematic review and MA of all available NOX2(-/y) studies revealed a positive publication bias and lack of statistical power to detect a relevant reduction in infarct size. A fully powered multi-center pRCT rejects NOX2 as a target to improve neurofunctional outcomes or achieve a translationally relevant infarct size reduction. Thus stringent statistical thresholds, reporting negative data and a MA-pRCT approach can ensure biomedical data validity and overcome risks of bias.
No takes yet. Share an insight, caveat, or question.
Kleikers et al. (2015) conducted an RCT in Ischemic stroke. NOX2 target validation / NOX2(-/y) was evaluated on Neurofunctional outcomes and infarct size reduction. Targeting NOX2 in a multi-center pre-clinical randomized confirmatory trial failed to improve neurofunctional outcomes or achieve a translationally relevant reduction in infarct size.
Synapse has enriched 10 related papers. Consider them for comparative context: